These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 30018250)

  • 21. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
    Zhang L; Wang Y; Li Z; Lin D; Liu Y; Zhou L; Wang D; Wu A; Li Z
    Diagn Pathol; 2021 May; 16(1):38. PubMed ID: 33933102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.
    Kim YB; Ahn JM; Bae WJ; Sung CO; Lee D
    Int J Cancer; 2019 Aug; 145(4):916-926. PubMed ID: 30664822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epstein-Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy.
    Pereira MA; Batista DAM; Ramos MFKP; Cardili L; Ribeiro RRE; Dias AR; Zilberstein B; Ribeiro U; Cecconello I; Alves VAF; Mello ES
    J Surg Res; 2021 May; 261():130-138. PubMed ID: 33429221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PIK3CA mutation subtype delineates distinct immune profiles in gastric carcinoma.
    Choi S; Kim H; Heo YJ; Kang SY; Ahn S; Lee J; Kim KM
    J Pathol; 2023 Aug; 260(4):443-454. PubMed ID: 37341658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subtraction of Epstein-Barr virus and microsatellite instability genotypes from the Lauren histotypes: Combined molecular and histologic subtyping with clinicopathological and prognostic significance validated in a cohort of 1,248 cases.
    Huang SC; Ng KF; Yeh TS; Cheng CT; Lin JS; Liu YJ; Chuang HC; Chen TC
    Int J Cancer; 2019 Dec; 145(12):3218-3230. PubMed ID: 30771224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
    Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
    Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial.
    Roh CK; Choi YY; Choi S; Seo WJ; Cho M; Jang E; Son T; Kim HI; Kim H; Hyung WJ; Huh YM; Noh SH; Cheong JH
    Yonsei Med J; 2019 Feb; 60(2):132-139. PubMed ID: 30666834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [PD-L1 expression in EBV-associated gastric carcinomas].
    Danilova NV; Sotnikova TN; Kalinin DV; Oleynikova NA; Chayka AV; Khomyakov VM; Kakotkin VV; Vychuzhanin DV; Andreeva YY; Malkov PG
    Arkh Patol; 2022; 84(4):5-12. PubMed ID: 35880594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials.
    Biesma HD; Soeratram TTD; Sikorska K; Caspers IA; van Essen HF; Egthuijsen JMP; Mookhoek A; van Laarhoven HWM; van Berge Henegouwen MI; Nordsmark M; van der Peet DL; Warmerdam FARM; Geenen MM; Loosveld OJL; Portielje JEA; Los M; Heideman DAM; Meershoek-Klein Kranenbarg E; Hartgrink HH; van Sandick J; Verheij M; van de Velde CJH; Cats A; Ylstra B; van Grieken NCT
    Gastric Cancer; 2022 May; 25(3):640-651. PubMed ID: 35129727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Significance of Tumor and Immune Cell PD-L1 Expression in Gastric Adenocarcinoma.
    Kim DH; Bae GE; Suh KS; Ryuman D; Song KS; Kim JS; Lee SI; Yeo MK
    In Vivo; 2020; 34(6):3171-3180. PubMed ID: 33144421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.
    Panda A; Mehnert JM; Hirshfield KM; Riedlinger G; Damare S; Saunders T; Kane M; Sokol L; Stein MN; Poplin E; Rodriguez-Rodriguez L; Silk AW; Aisner J; Chan N; Malhotra J; Frankel M; Kaufman HL; Ali S; Ross JS; White EP; Bhanot G; Ganesan S
    J Natl Cancer Inst; 2018 Mar; 110(3):316-320. PubMed ID: 29155997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein-Barr Virus-associated gastric carcinoma.
    Nakayama A; Abe H; Kunita A; Saito R; Kanda T; Yamashita H; Seto Y; Ishikawa S; Fukayama M
    PLoS One; 2019; 14(1):e0211358. PubMed ID: 30695048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions.
    Sasaki S; Nishikawa J; Sakai K; Iizasa H; Yoshiyama H; Yanagihara M; Shuto T; Shimokuri K; Kanda T; Suehiro Y; Yamasaki T; Sakaida I
    Gastric Cancer; 2019 May; 22(3):486-496. PubMed ID: 30264329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-L1 Antibodies for EBV-Positive Gastric Cancer, Going Beyond PD-L1 Expression and Microsatellite Instability.
    Almhanna K; Antonia S
    J Natl Cancer Inst; 2018 Mar; 110(3):221-222. PubMed ID: 29155933
    [No Abstract]   [Full Text] [Related]  

  • 35. IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma.
    Moon JW; Kong SK; Kim BS; Kim HJ; Lim H; Noh K; Kim Y; Choi JW; Lee JH; Kim YS
    Sci Rep; 2017 Dec; 7(1):17810. PubMed ID: 29259270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1.
    Pereira MA; Ramos MFKP; Dias AR; Faraj SF; Ribeiro RRE; de Castria TB; Zilberstein B; Alves VAF; Ribeiro U; de Mello ES
    Mol Diagn Ther; 2019 Dec; 23(6):761-771. PubMed ID: 31595457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma.
    Kang GH; Lee S; Kim WH; Lee HW; Kim JC; Rhyu MG; Ro JY
    Am J Pathol; 2002 Mar; 160(3):787-94. PubMed ID: 11891177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study.
    Choi YY; Kim H; Shin SJ; Kim HY; Lee J; Yang HK; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Choi SH; Hong S; Kim JW; Hyung WJ; Noh SH; Cheong JH
    Ann Surg; 2019 Aug; 270(2):309-316. PubMed ID: 29727332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological characteristics of Epstein-Barr virus and microsatellite instability subtypes of early gastric neoplasms classified by the Japanese and the World Health Organization criteria.
    Tanabe H; Mizukami Y; Takei H; Tamamura N; Omura Y; Kobayashi Y; Murakami Y; Kunogi T; Sasaki T; Takahashi K; Ando K; Ueno N; Kashima S; Yuzawa S; Hasegawa K; Sumi Y; Tanino M; Fujiya M; Okumura T
    J Pathol Clin Res; 2021 Jul; 7(4):397-409. PubMed ID: 33750036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EBV⁺ and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8⁺ Intratumoral Lymphocytes.
    De Rosa S; Sahnane N; Tibiletti MG; Magnoli F; Vanoli A; Sessa F; Chiaravalli AM
    Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29614789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.